Klaria Pharma

Summary of the Year-End Report

Successful rights issue brought 59.2 MSEK to Klaria

New collaboration agreement signed with PharmaMar fourth quarter of 2022

- Net sales amounted to 2.2 MSEK (0.0 MSEK)

- Other income amounted to 0.2 MSEK (6.2 MSEK)

- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)

- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)

- Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK)

- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)

- Equity as of December 31 amounted to 76.0 MSEK (69.4 MSEK) The period January-December 2021

- Net sales amounted to 5.9 MSEK (0.0 MSEK)

- Other income amounted to 0,7 MSEK (37.5 MSEK)

- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)

- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)

- Earnings per share for the quarter amounted to -1.10 SEK (-1.03 SEK)

- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)

- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)

- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)